Ferroptosis-related gene signature predicts prognosis and immunotherapy response in hepatocellular carcinoma: A multi-cohort retrospective study
Open Access
- 23 January 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (4) , e47262
Abstract
Hepatocellular carcinoma (HCC), characterized by elevated incidence and mortality rates, has a considerable economic impact worldwide. The function of ferroptosis within the tumor microenvironment of HCC is crucial, and the specific contributions of ferroptosis-related genes (FRGs) are yet to be fully explored. FRG expression levels and relevant clinical data were sourced from The Cancer Genome Atlas. Two distinct ferroptosis-related subtypes were identified in liver cancer and their interrelationships were comprehensively examined. Using Cox regression and least absolute shrinkage and selection operator regression analysis, we created a predictive model based on FRGs to forecast overall survival and assess the potential benefits of immunotherapy in patients with HCC. Quantitative reverse transcription-polymerase chain reaction and IHC assays were conducted on clinical HCC specimens to validate the key FRGs. Significant differences in gene mutations, immune reactions, and prognostic outcomes were observed between the 2 distinct ferroptosis-related subtypes. An eight-gene signature consisting of SLC1A5, KIF20A, SLC7A11, CARS1, MYCN, PRDX6, GPX4, and KLF2 was established as a predictive model for liver cancer and was validated against data from GSE76427 and the International Cancer Genome Consortium cohorts. According to the FRG model, individuals classified as low-risk exhibited more favorable survival prospects compared to their high-risk counterparts ( P < .05). Overall, our investigation highlights the promise of FRGs as prognostic biomarkers and immunotherapy response in HCC, providing a novel approach for personalized patient management.Keywords
This publication has 49 references indexed in Scilit:
- Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11Cancer Discovery, 2019
- CD8+ T cells regulate tumour ferroptosis during cancer immunotherapyNature, 2019
- Molecular therapies and precision medicine for hepatocellular carcinomaNature Reviews Clinical Oncology, 2018
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialThe Lancet, 2018
- Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and DiseaseCell, 2017
- Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint BlockadeCell Reports, 2017
- TCGA Workflow: Analyze cancer genomics and epigenomics data using Bioconductor packagesF1000Research, 2016
- limma powers differential expression analyses for RNA-sequencing and microarray studiesNucleic Acids Research, 2015
- GSVA: gene set variation analysis for microarray and RNA-Seq dataBMC Bioinformatics, 2013
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell DeathCell, 2012